Analgesic Nephropathy

Analgesic nephropathy is a part of the wider clinical ‘analgesic’ syndrome, which includes neuropsychiatric, gastrointestinal, haematological, cardiovascular, and dermatological manifestations in addition to the increased risk of developing Urothelial tumours. Although the major malignancy that has been observed in association with Analgesic Nephropathy is transitional cell carcinoma, other cancers such as renal cell carcinoma and sarcoma has also been reported in the literature. Analgesic-associated tumours are more likely to be multifocal and more malignant than those unrelated to analgesics. These tumours are more likely of renal pelvic origin with frequent accompaniment of renal papillary necrosis and kidney dysfunction. A mean phenacetin consumption of 9.1 kg, a mean exposure time of 17 years, a mean induction time of 22 years, and female sex have been reported as risk factors for these tumours.

  • Pathological abnormalities in kidney
  • Arterial occlusion of renal artery
  • Impairment of moderate renal

Related Conference of Analgesic Nephropathy

November 16-17, 2018

5th International Conference on Rhinology and Otology

Melbourne, Australia
November 22-23, 2018

World Congress on Surgeons

Bucharest, Romania
December 13-14, 2018

4th International Anesthesia and Pain Medicine Conference

Abu Dhabi, UAE
April 17-18, 2019

World Congress on Cardiac Surgery & Medical Devices 2019

Montreal | Quebec | Canada
May 22-23, 2019

10th International Congress on Surgery

Tokyo, Japan
June 19-20, 2019

13th International Conference on Surgery and Anaesthesia

Brisbane, Australia
July 01-02, 2019

4th International Conference on Anesthesia

Valencia, Spain
August 02-03, 2019

2nd International Conference on Plastic & Cosmetic Surgery

August 02-03, 2019 | Chicago, USA

Analgesic Nephropathy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in